THROMBOGENICS

EMA's CHMP Recommends Approval of Novartis' Jetrea for Vitreomacular Traction Treatment

- Novartis' eye care division Alcon receives positive CHMP opinion for Jetrea (ocriplasmin) to treat vitreomacular traction and associated macular holes in European patients. - The innovative treatment addresses an unmet need for 250,000-300,000 European patients with VMT, offering an alternative to the current 'watchful waiting' approach before late-stage surgery. - Following FDA approval in October 2012, Europe is set to become the first region outside the US to approve Jetrea, marking a significant advancement in retinal therapy.